An interventional study of Novel Flow Diverter Stent in Intracranial Aneurysm, sponsored by Beijing Tiantan Hospital. Recruiting at 1 site in China. Open to participants aged 22 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-16.
Sponsored by Beijing Tiantan Hospital · Not applicable, Interventional, and Treatment
Among 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital — 7 open to participants now, 8 under way, 1 of them phase 3. Intracranial Aneurysm · Beijing Tiantan Hospital.
Among the 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital, this one is the only one that started in 2026, is one of 5 with no phase, and was the 19th registered.
418 studies on the registry are indexed under Intracranial Aneurysm; 119 are open to participants now.
Browse Intracranial Aneurysm studies →7 of the 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital are open now, in 1 country. Recruiting first, the newest first:
Beijing Tiantan Hospital · Sites in China
Ages 18–75
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18–80
Beijing Tiantan Hospital · Sites in China
Ages 18+
Beijing Tiantan Hospital · Sites in China
Ages 18–80
By country, each count listing its studies:
Of the 82 Intracranial Aneurysm studies recruiting now, 49 (60%) set no upper age limit and 14 (17%) stop at 75 or younger; 15 take children under 18; 6 take healthy volunteers.
This study: 22 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 280 is above the median of 100 across 207 interventional studies indexed under Intracranial Aneurysm.
Median enrollment 499 across the 8 interventional studies, 1,500 across the 12 observational. Of the 7 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Beijing Tiantan Hospital is the lead sponsor of 489 studies on the registry; 293 are open to participants now.
2 of the studies in Intracranial Aneurysm by Beijing Tiantan Hospital that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07089862Beijing Tiantan HospitalINdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT) | 2026-12-31 |
| NCT06364293Beijing Tiantan HospitalAn Early Warning Model of Unfavorable Outcomes Following Endovascular Interventional Treatment of Intracranial Aneurysm | 2026-12-31 |
Among the 20 studies in Intracranial Aneurysm by Beijing Tiantan Hospital, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intracranial aneurysm, as a common cerebrovascular disease, has a variety of treatment methods, including surgical treatment and endovascular treatment. Among these treatment methods, flow diverters have attracted much attention due to their unique therapeutic principles. Flow diverters help promote thrombus formation within the aneurysm by altering the direction and dynamics of blood flow, thereby achieving the purpose of treatment. 1-5 Flow diverters such as the Pipeline™ device have been proven to be safe and effective for the treatment of intracranial aneurysms and have gradually been recognized as the preferred device for the management of intracranial aneurysms.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Age 22 to 80 years.
Diagnosed with intracranial wide-neck aneurysm and planned for treatment with a flow diverter stent.
Parent artery distal/proximal diameter compatible with available sizes and models of flow diverter stents, and treatment to be performed in accordance with the China NMPA-approved indications and instructions for use.
Exclusion Criteria:
Prior intracranial implant (e.g., coils) in the target intracranial aneurysm territory within 6 months before enrollment.
Prior surgery, including endovascular treatment, within 30 days before enrollment.
Modified Rankin Scale (mRS) score ≥ 3.
Any known to flow diverter stent treatment or antiplatelet therapy, including contraindications to dual antiplatelet therapy (DAPT).
Pre-existing stent/flow diverter placed in the parent artery of the target aneurysm location.
Investigator judges that the patient's health or the validity of study results (e.g., high risk of neurological events, conditions that may increase the chance of stroke) could be compromised by study participation.
Women who are pregnant, breastfeeding, or planning to become pregnant during the study period.
Known allergy to platinum or cobalt-chromium alloys (including major elements: platinum, cobalt, chromium, nickel, or molybdenum).
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Novel Flow Diverter Stent
Patients with intracranial wide-neck aneurysms undergo implantation of new generation flow diverter stents (e.g., Pipeline Shield, Lattice, etc.) per IFU and local practice. Stent reconstructs parent artery, diverts flow, promoting aneurysm thrombosis. Concomitant antiplatelet therapy (DAPT: aspirin + clopidogrel/ticagrelor) given per guidelines, continued ≥3-6 months post-procedure. This is a prospective, multicenter, single-arm, real-world study in China (≈15 sites, N=280). Follow-up: 30d, 6m, 1y, then annually to 4y post-procedure, including clinical (mRS) and imaging (DSA/CTA) assessments.
Aneurysm Complete Occlusion Rate
Proportion of patients with complete occlusion of the target aneurysm at 1 year post-procedure, as assessed by the core imaging laboratory using the Raymond-Roy Occlusion Classification (Class I: complete obliteration).
Time frame: 1 year post-procedure
Plan to share: No
Started Jan 2026 (actual). Primary completion is estimated for Aug 2030, 55 months after the start.
Of 56 non-industry interventional studies with no phase under Intracranial Aneurysm, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 134. This study's planned 55 months is close to that.
Counting every sponsor, half of 104 studies reached it within 39 months; a quarter within 22 and three quarters within 69.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.